Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoSTING

OncoSTING
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$150K LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of therapies intended to cure bladder cancer. The company is developing novel bladder cancer therapies that work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Baltimore, MD
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoSTING’s full profile, request a free trial.

OncoSTING Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 02-Jul-2019 $150K 00000 Completed Startup
2. Grant 01-Jul-2018 Completed Startup
1. Grant 23-Feb-2018 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

OncoSTING Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Johns Hopkins University Endowment Limited Partner 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0

OncoSTING Executive Team (3)

Name Title Board
Seat
Contact
Info
Trinity Bivalacqua Ph.D Co-Founder
William Bishai Ph.D Co-Founder
Sebastian Seiguer JD Advisor